Resource impact summary report
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect local data and assumptions.
NICE has recommended zanubrutinib within its marketing authorisation, as an option for treating marginal zone lymphoma in adults who have had at least 1 anti-CD20-based treatment. It is only recommended if the company provides it according to the commercial arrangement.
Eligible population for zanubrutinib
Table 1 shows the population who are eligible for zanubrutinib and the number of people who are expected to have zanubrutinib in each of the next 5 years including population growth.
| Eligible population and uptake | Current practice | 2024-25 | 2025-26 | 2026-27 | 2027-28 | 2028-29 |
|---|---|---|---|---|---|---|
|
People eligible for zanubrutinib |
260 |
270 |
270 |
270 |
280 |
280 |
|
Uptake for zanubrutinib (%) |
0% |
25% |
50% |
50% |
50% |
50% |
|
People starting zanubrutinib each year |
0 |
70 |
140 |
140 |
140 |
140 |
The uptake for zanubrutinib is an estimate based on a NICE estimate.
Treatment options for the eligible population
The most common second-line and beyond treatment for relapsed or refractory marginal zone lymphoma is rituximab with or without chemotherapy or chemotherapy alone.
Zanubrutinib is an oral treatment and can be easily administered and fitted into the existing care pathway. Comparator treatments are administered by intravenous infusion or orally.
For more information about the treatments, such as dose and average treatment duration, see the resource impact template.
Financial resource impact (cash items)
The company has a commercial arrangement. This makes zanubrutinib available to the NHS with a discount.
Users can input the confidential price of zanubrutinib and amend other variables in the resource impact template.
The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.
For further analysis or to calculate the financial impact of cash items, see the resource impact template.
Capacity impact
Zanubrutinib is administered orally and will likely reduce the number of intravenous infusions required in treatment when compared with most of the comparator treatments.
Key information
| Time from publication to routine commissioning funding |
90 days |
|---|---|
| Programme budgeting category |
PBC 02I |
| Commissioner(s) |
NHS England |
| Provider(s) |
NHS hospital trusts |
| Pathway position |
Second line |
About this resource impact summary report
This resource impact summary report accompanies the NICE guidance on zanubrutinib for treating relapsed or refractory marginal zone lymphoma and should be read with it. See terms and conditions and on the NICE website.
ISBN: 978-1-4731-6541-0